Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
PRNewswire - December 12, 2007
WALTHAM, Mass., Dec. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Johnson & Johnson's Prezista and Wyeth's Pristiq will fall short of blockbuster status owing to payer restrictions. Although Prezista has received favorable tier placement and patient advocacy and is recognized as providing a significant therapeutic advance, the current target population for the drug is very small. Prezista is currently approved, in combination with Abbott's Norvir, for treatment-experienced HIV patients that have failed more than one protease inhibitor. However, payers in the United States and Europe are likely to restrict reimbursement to treatment- experienced HIV patients, limiting the potential for the drug. Unlike Prezista, Pristiq is perceived by U.S. and European payers to have little or no value over its predecessor drug. Therefore, unfavorable reimbursement in Europe and payer controls such as third tier status with restrictions in the U.S. will limit the use of the product.
The new special report entitled Potential Blockbusters: U.S. and European Payers Share Insight on Which Brands Will Succeed and Which Will Fall Short also finds that U.S. and European payers expect to increase restrictions on reimbursement of high-priced oncology products and will increasingly define specific patient populations eligible for reimbursement. The question of value in premium-priced oncology agents is already evident in current U.S. payer behavior. This report indicates that up to 25% of managed care organizations do not cover both agents when two similar targeted agents are available. Marketers of Tykerb, Nexavar, Sutent, and Bristol-Myers Squibb's Sprycel need to address the fact that some managed care organizations appear to perceive Herceptin/Tykerb, Nexavar/Sutent and Novartis's Gleevec/Sprycel as three pairs of interchangeable "me-too" agents.
"In this increasingly cost-conscious environment, the pharmaceutical industry is aware that for a drug to be successful, the company needs to understand not only how and to what extent physicians will use the agent but also how payers will frame their reimbursement decisions -- especially for drugs that could reach or exceed $1 billion in sales," said Alice von Loesecke, Ph.D., senior director at Decision Resources. "We found that payers may have very different needs when it comes to the product and disease- specific data that pharmaceutical companies should provide to maximize the value of their product in the payer's mind. In communicating product value, companies also have powerful allies -- the physicians and patients."
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall | Decision Resources, Inc. | 781-296-2563 | emarshall@dresources.com
Source: Decision Resources
Web site: http://www.decisionresources.com/
071212
PR071229
Copyright © 2007 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .